Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
– No differentiation syndrome events reported –
– 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML –
– 56% CR/CRh with ven/aza in menin inhibitor naïve patients with R/R AML –
Related news for (KURA)
- Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
- Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
- 24/7 Market News Snapshot 02 June, 2025 – Kura Oncology, Inc. (NASDAQ:KURA)
- Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
- Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting